Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04471441
Other study ID # B95-02LT1903
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date June 30, 2020
Est. completion date November 17, 2022

Study information

Verified date July 2020
Source Chong Kun Dang Pharmaceutical
Contact Soon Il Kim, M.D., Ph.D.
Phone 82-2-2228-2131
Email SOONKIM@YUHS.AC
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of CertiroBell® tablet compared with mycophenolate mofetil in primary living donor liver transplant recipients.


Description:

This study is multi-center, open-label, randomized controlled phase 4 study to evaluate the efficacy and safety of certirobell® tablet compared with mycophenolate mofetil in primary living donor liver transplant recipients.

On the first visit the patients scheduled to be operated liver transplant in 35 days will be conducted screening. Patients who meet the criteria of this clinical trial will be randomized to CertiroBell or mycophenolate mofetil on the second visit. Each group will take CertiroBell or mycophenolate mofetil and will conduct scheduled tests with 5 additional visits.


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date November 17, 2022
Est. primary completion date September 13, 2022
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility * Inclusion Criteria:

[Time of screening]

- Patients who have transplanted in primary living donor liver in 35 days or who plan to be transplanted in primary living donor liver.

- Over 20 years old(male or female)

- Agreement with written informed consent

[Time of randomization] - Patients who have transplanted liver within 4 weeks(25 days to 35 days)

* Exclusion Criteria

[Time of screening]

- Patients who have transplanted non-liver organs or have plan to be transplanted non-liver organs.

- Patients with bioartificial liver (cell system)

- Patients who diagnosed with malignant tumor within 5 years [however, who have recovered from skin cancer (squamous cell/basal cell carcinoma) or thyroid cancer, hepatocellular carcinoma without main vessel invasion or extrahepatic metastasis can be enrolled]

- Patients with severe systemic infection

- Women who are pregnant or breast feeding or not agree to the proper use of contraception during the trial

- Participated in other trial within 4 weeks

- In investigator's judgement

[Time of randomization]

- Patients with acute rejection who have been clinically treated after liver transplantation.

- Patients with complication related to the hepatic artery such as hepatic artery thrombosis at the time of randomization.

- At screening

- WBC <1,500/mm^3 or PLT <30,000/mm^3 or over 3 times upper than normal range of liver function tests(T-bilirubin, AST, ALT) levels

- Protein/Creatinine ratio(urine test) > 1 or eGFR by MDRD< 30mL/min/1.73m^2 or Total cholesterol > 350mg/dL or triglycerides > 500mg/dL

- Patients taking HCV(hepatitis C virus) Therapeutic Drugs

- Patients who had plasmapheresis within 1 week.

- Patents who had a record of taking mTOR inhibitor before.

- In investigator's judgement

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Everolimus Tab.
After first dose 1mg BID(total 2mg daily PO), check the blood concentration of everolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 3~8ng/mL.
Mycophenolate mofetil Tab./Cap.
Up to 1.5g BID(total 3g daily), PO

Locations

Country Name City State
Korea, Republic of Severance Hospital Seoul

Sponsors (1)

Lead Sponsor Collaborator
Chong Kun Dang Pharmaceutical

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of composite efficacy failure composite efficacy failure include biopsy-confirmed acute rejection, graft loss, death, or follow-up failure until 24 weeks after taking medicine
Secondary Incidence of biopsy-confirmed acute rejection acute rejection confirmed by result of biopsy(over 4 points of RAI score) until 24weeks and 48weeks after taking medicine
Secondary The pathological results and time of occurrence and method of treatment, result of the treatment of acute rejection confirmed by biopsy(over 4 points of RAI score) details of acute rejection confirmed by result of biopsy(over 4 points of RAI score) until 24weeks and 48weeks after taking medicine
Secondary Incidence of composite efficacy failure composite efficacy failure include biopsy-confirmed acute rejection, graft loss, death, or follow-up failure until 48weeks after taking medicine
Secondary Survival rate of patients Survival rate of patients until 24weeks and 48weeks after taking medicine
Secondary Survival rate of transplanted organ Survival rate of transplanted organ until 24weeks and 48weeks after taking medicine
Secondary Incidence and recurrence rates of liver cancer Incidence and recurrence rates of liver cancer until 24weeks and 48weeks after taking medicine
Secondary Incidence and recurrence rates of HCV infection Incidence and recurrence rates of HCV infection until 24weeks and 48weeks after taking medicine
Secondary Incidence of CMV infection Incidence of CMV infection until 24weeks and 48weeks after taking medicine
Secondary variation of Serum creatinine, eGFR(estimated glomerular filtration rate) compared to the baseline eGFR using MDRD(Modification of Diet in Renal Disease) method at 24 weeks and 48weeks
See also
  Status Clinical Trial Phase
Completed NCT02798861 - Controlled Attenuation Parameter (CAP) in Liver Allografts
Completed NCT03527238 - Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine Phase 2
Completed NCT01696331 - Text Messaging for Adherence in Adolescent Liver Transplant Recipients N/A
Recruiting NCT05051605 - Immune Response to COVID-19 Vaccine in Recipients of Living Donor Liver Transplantation
Recruiting NCT05940857 - Sponsor-Initiated OCS Liver Perfusion (OLP-II) Registry
Completed NCT01598987 - Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients. Phase 3
Active, not recruiting NCT05074160 - OCS Liver Perfusion (OLP) Post-Approval Registry
Completed NCT05087550 - Multicenter Study on Organ Acquisition Costs in the Post Re-Allocation Era: Liver Transplantation
Recruiting NCT04836923 - LIFT Intervention in Liver Transplant Candidates N/A
Not yet recruiting NCT03666689 - Outflow Reconstruction in Right Lobe Living Donor Liver Transplantation
Not yet recruiting NCT06088758 - Normothermic Machine Perfusion of Steatotic Livers for Expansion of Donor Organ Pool N/A
Terminated NCT01230502 - Mycophenolic Acid (MPA) Monotherapy in Liver Transplantation N/A
Completed NCT00171509 - Efficacy and Safety of Cyclosporine Microemulsion Given Once a Day in Adult Stable Liver Transplant Recipients Phase 4
Not yet recruiting NCT06254248 - Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma Phase 2
Recruiting NCT06075745 - Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates Phase 2
Completed NCT02057484 - A 5 Year Follow-up of Patients Who Were Previously Enrolled Into an Advagraf Trial Following a Liver or Kidney Transplant
Active, not recruiting NCT03577431 - Liver Transplantation With Tregs at MGH Phase 1/Phase 2
Recruiting NCT06342557 - Transitional ePRO Diary Liver
Not yet recruiting NCT04265157 - Hepato-duodenal Ligament Occlusion and Classic Technique in Liver Transplant
Recruiting NCT02863250 - Australian and New Zealand Massive Transfusion Registry